Gedeon Richter Spends Most On Biosimilar R&D
Multiple Candidates In Clinical Phase Including Denosumab
Hungary’s Gedeon Richter enjoyed “rapid sales growth” for its Terrosa teriparatide biosimilar in the first nine months of this year, justifying the firm’s continued advance into biosimilar development.
